Effect of antibiotic therapy in patients with ulcerative colitis: a meta-analysis of randomized controlled trials

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet (London, England). 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014; 63(8):1275–1283.
   PubMed Web of Science ®Google Scholar
• Lepage P, Hasler R, Spehlmann ME, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141(1):227–236.
   PubMed Web of Science ®Google Scholar
• Shen ZH, Zhu CX, Quan YS, et al. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018; 24(1):5–14.
   PubMed Web of Science ®Google Scholar
• Gao J, Gillilland MG, 3rd, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes. 2014;5(4):571–575.
   PubMed Web of Science ®Google Scholar
• Pelissier MA, Vasquez N, Balamurugan R, et al. Metronidazole effects on microbiota and mucus layer thickness in the rat gut. FEMS Microbiol Ecol. 2010;73(3):601–610.
   PubMed Web of Science ®Google Scholar
• Ledder O, Turner D. Antibiotics in IBD: still a role in the biological era? Inflamm Bowel Dis. 2018; 24(8):1676–1688.
   PubMed Web of Science ®Google Scholar
• Madsen KL, Doyle JS, Tavernini MM, et al. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology. 2000; 118(6):1094–1105.
   PubMed Web of Science ®Google Scholar
• Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun. 2001;69(4):2277–2285.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol. 1997;92(3):454–456.
   PubMed Web of Science ®Google Scholar
• Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998;115(5):1072–1078.
   PubMed Web of Science ®Google Scholar
• Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012;4(6):1051–1056.
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci. 2007;52(11):2920–2925.
   PubMed Web of Science ®Google Scholar
• Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661–673.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, Cochrane Statistical Methods Group, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928:
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Dickinson RJ, O'Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985;26(12):1380–1384.
   PubMed Web of Science ®Google Scholar
• Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986;27(10):1210–1212.
   PubMed Web of Science ®Google Scholar
• Burke DA, Axon AT, Clayden SA, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1990;4(2):123–129.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Hatzis A, Kontogiannis P, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol. 1994;89(1):43–46.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial [1]. Dig Dis Sci. 1999;44(6):1220–1221.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001;36(9):971–974.
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Nomura T, Terai T, et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol. 2005;40(11):1334–1342.
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105(8):1820–1829.
   PubMed Web of Science ®Google Scholar
• Petersen AM, Mirsepasi H, Halkjaer SI, et al. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohn's Colitis. 2014;8(11):1498–1505.
   Google Scholar
• Turner D, Bishai J, Reshef L, et al. Antibiotic cocktail for pediatric acute severe colitis and the microbiome: the PRASCO randomized controlled trial. Inflamm Bowel Dis. 2020;26(11):1733–1742.
   PubMed Web of Science ®Google Scholar
• Lobo AJ, Burke DA, Sobala GM, et al. Axon AT: oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther. 1993;7(2):155–158.
   PubMed Web of Science ®Google Scholar
• Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, et al. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev. 2019;32(2):e00060–18.
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Sato N, Ogihara T, et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol. 2002;17(8):849–853.
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Okayasu I, Ogihara T, et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2003;52(1):79–83.
   PubMed Web of Science ®Google Scholar
• Kato K, Ohkusa T, Terao S, et al. Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2014;39(9):949–956.
   PubMed Web of Science ®Google Scholar